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Preface
One famous saying by Robert Louis Stevenson “It is not a hard thing to know what to write;
the hard thing is to know what to leave out" holds very true for us while writing the preface
of this book.
Tuberculosis (TB) is as old as mankind and continues to haunt the mankind despite several
spectacular advances in the diagnosis and management of TB. TB is the commonest single
infectious cause of death and accountable for over 25% of avoidable deaths worldwide but
can still be labeled as “Captain of all these men of death”.
In the initial sections of the book chapters covering the basic pathophysiology and the im‐
portant factors contributing to the same viz. epidemiology of TB, iron metabolism, unusual
properties of M. Tuberculosis, lipid inclusion, role of small regulatory RNA and adaptation
to survival in human host, which makes it “tough bug” to treat, has been included in details.
Our understanding of the host pathogen interaction at the molecular level, especially immu‐
nopathogenesis of TB has improved enormously and has been extensively covered in the
book. Chapters have been included to cover several new drug and potential vaccines for TB.
New development such as the interferon-gamma release assays [IGRAs] for latent TB infec‐
tion, use of liquid culture and molecular method of diagnosis are ushering in a new era in
TB diagnostics. Comprehensive knowledge of latest modes of diagnosis has been also incor‐
porated in the book. Furthermore, issues concerning quality assurance in antituberculosis
drug susceptibility testing are getting established.
Data are rapidly accumulating from all over the world regarding the efficacy of standar‐
dized treatment regimens for drug-sensitive, drug-resistant TB and latent TB infection.
While we are facing the menace of multi drug-resistant TB [MDR-TB], extensively drug-re‐
sistant tuberculosis [XDR¬ TB] has emerged threatening to undermine global efforts at TB
control. Hence we have included chapters to cover all aspects of the diagnosis and manage‐
ment of MDR TB. This book will cover all these developments in great detail.
With the widespread availability of internet globally various standard web resources availa‐
ble on TB have also been included so that the readers may get the comprehensive and up‐
dated guidelines from these resources. The changing clinical presentation of TB, advances in
laboratory, imaging diagnostic modalities, therapeutic measures and emergence of MDR TB
all suggest a pressing need to have a updated book on TB. Furthermore, while all physicians
encounter the TB disease in their clinical practice, there have been a lot of controversies and
misconceptions over various issues for the diagnosis and management of TB.
Paucity of a well referenced, updated, standard book of TB has prompted us to undertake
this venture sharing the clinical experience of global experts of TB.
Our book contains chapters on epidemiology, immune-pathology, diagnosis, treatment and
latest advances for TB, highlighting the global perspective of tuberculosis. World-wide re‐
surgence of MDR TB indicates that the battle against this foe of mankind will continue in the
coming years. TB still remains to be a research priority of paramount importance from
medical, social and financial aspects and we have attempted to highlight all the aspects for
the treatment of TB.
We believe that this book will serve as a practical guide for the diagnosis and management
of TB for practicing physicians (especially pulmonologists and internists) and all those who
are involved in the management of TB.
This book has several contributors, all of them leading authorities from various parts of the
world. All the chapters have been thoroughly re-written and updated with preservation of the
views of the contributors in a uniform format. This effort would not have been possible without
the kind cooperation of our contributors who patiently went through revisions and updating
of their chapters. We convey our heartfelt thanks to all contributors and to InTech Publisher,
Croatia for their encouragement and excellent technical assistance as and when required.
Lastly we would like to thank the almighty god, our parents, wives and children, without
their untiring support and encouragement this book would not have seen the light of the day.
Editor:
Dr. Bassam H. Mahboub
Director, Department of Pulmonary Medicine and Allergy,
Rashid Hospital & Dubai Hospital, Dubai;
Assistant Professor, Dept of Medicine & Respiratory Disease & Allergy,
University of Sharjah, UAE
Co-editor:
Dr. Mayank G. Vats
Senior Specialist, Pulmonologist,
Intensivist & Sleep Physician,
Rashid Hospital, Dubai Health Authority,
Dubai, UAE
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1. Introduction
Tuberculosis is still one of the leading causes of death by infectious diseases with 2 million
deaths per year and 9.2 million new cases of tuberculosis disease annually [1-3]. Besides, more
than 2 milliard people are infected with latent tuberculosis infection (LTBI) [1-3]. Despite
continuous effort in the prevention, monitoring and treatment of tuberculosis, the disease
remains a major health problem in many countries [4-6], particularly in developing countries
like Indonesia [7]. National tuberculosis programs and other programs conducted by foreign
organizations still fail to eliminate the transmission and incidence of tuberculosis. Transmis‐
sion is even on the rise in developing countries despite the availability of effective therapies
for tuberculosis, whereas the spread and the incidence of tuberculosis in Europe and North
America are under control. Several reasons may be responsible for this failure, such us the
difficulty of providing adequate anti-tuberculosis medication in many developing countries
due to cost issues, the emergence of multi-drug resistant (MDR) strains of M. tuberculosis, and
the dramatically high co-incidence of tuberculosis in HIV-infected patients [2, 7]. Another
important issue is delay of diagnosis due to the lack of a proper method to identify tuberculosis
agents [1, 8].
Smear is the cheapest and most widely available detection method for M. tuberculosis. In this
technique, the diagnosis of tuberculosis is based on identification of acid-fast bacilli (AFB) in
a patient`s sputum [9, 10]. Many staining techniques are available for AFB smear, the most
common one of which is the modified Ziehl-Neelsen stain. Unfortunately, the sensitivity and
the specificity of those techniques are low due to difficulty in the identification and differen‐
tiation of the various species of M. tuberculosis [10]. Two studies found that the AFB smear was
positive in only half of patients with subsequent culture positive for M. tuberculosis [9, 10].
Another worldwide available detection method is the conventional culture method on
© 2013 Hatta and Sultan; licensee InTech. This is an open access article distributed under the terms of the
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Lowenstein-Jensen (LJ) medium. This method is the gold standard in the identification of M.
tuberculosis and still serves as the reference method due to its high sensitivity (89%) and
specificity (98%) [4, 7, 9, 10]. However, this technique requires equipments or materials that
are often unavailable in resource-poor settings. In addition, this technique is time consuming;
the results only can be obtained after 6–12 weeks. In addition, the incidence of other bacterial
contamination on culture tends to be high [7, 11]. Even a modern culture method such as the
BACTEC MGIT 960 culture system, which uses the modified Middlebrook 7H9 broth and a
fluorescent signaling system, allows for earlier detection of growth, but still takes at least 10
days to give any result [9].
The  goal  of  tuberculosis  control  programs  is  to  identify  and  to  cure  as  many  cases  as
possible; therefore the critical role of early diagnosis is obvious [11]. Under-diagnosis may
lead to further spread of the disease because undiagnosed patients can spread the disease
unnoticeably  [11].  Accurate  and  early  diagnosis  is  the  first  important  step  to  effective
management.  Several  new  methods  for  the  identification  of  tuberculosis  are  available,
which including serologic tests and also various molecular methods developed as a result
of  major  advances in understanding the genetic  aspects  of  tuberculosis  [8,  9,  11].  Those
detection methods can be grouped into two types First,  by detection of mycobacteria or
its components directly; second by measurement of immunologic responses to mycobacte‐
rium  infection  [9].  In  this  chapter  we  present  a  short  review  of  some  these  promising
detection methods used in the laboratory to identify tuberculosis.
2. Direct detection methods
The genus mycobacterium consists of almost 100 different species, which all appear similar on
AFB staining and culture [7, 10, 12]. Many of these can be isolated from humans, although
many also can be found in the environment including in animals. It is not easy, however, to
distinguish between pathogen and saprophyte species. Each mycobacterium isolate must be
evaluated individually regarding its potential to cause a disease; therefore identification of
mycobactera is a lengthy and tedious effort. Since the introduction of nucleic acid amplification
assays as diagnostic tool for mycobacteria identification, several probes/gene amplification
systems for tuberculosis have been developed for rapid and specific identification of M.
tuberculosis and other mycobacteria [12, 13]. These techniques allow for the confirmation of
identity of isolates, direct detection of gene sequences from the clinical specimens and also for
molecular detection of drug resistance [12]. Many previous publications have shown the
sensitivity and specificity of several molecular detection assays such as BDProbeTec ET,
(Becton Dickinson), COBAS AMPLICOR (Roche), Amplified M. tuberculosis Direct Test
AMTDT (Gen Probe, USA) for identification of mycobacteria[9].
The use of nucleic-acid probe identification systems was a one step ahead in the rapid
identification of mycobacterium species of M. tuberculosis complex, M. avium complex, M.
Tuberculosis - Current Issues in Diagnosis and Management154
avium, M. intracellulare, M. kansasii, and M. gordonae and also other nontuberculous mycobac‐
teria (NTM) in culture because the result can be obtained after 2 hours [10, 12]. But the
sensitivity and specificity of this probe technology will only approximate 100% if there are
more than 100 mycobacteria present in the sample, except for M. kansasii (87%) [12]. Thus, these
probes are not sensitive enough to be used directly in clinical specimens like sputum. Also, it
still needs to be confirmed by other conventional detection methods such as biochemical test
and molecular tests to able to identify the species identity within the M. tuberculosis complex,
such as for M. microti, M. bovis, M. bovis of BCG,, M. canettii, and M. africanum [10]. There has
been extensive research to design an identification system for ribosomal RNA/DNA finger‐
printing and for development of probes that targeting specific rRNA, ribosomal DNA, spacer
and flanking sequences of various types of mycobacterium species including M. tuberculosis,
M. leprae, M. avium, M. gardonae, etc [12, 13]. Those rRNA targeting probes are 10-100 fold more
sensitive than DNA targeting. However, since the lowest detection limit is still around 100
organisms. it still needs more evaluation before it can be applied to clinical specimens [12].
Several techniques based on polymerase chain reaction (PCR) and isothermal amplification
assay have been developed [7-10, 12]. Various researchers have described the rapid detection
of M. tuberculosis by PCR, and many have reported a high sensitivity in detecting M. tubercu‐
losis in clinical samples by means of DNA amplifications [7, 14]. Such techniques involve
amplification of specific gene regions followed by hybridization with species specific primers,
and also frequently followed by sequencing and or restriction fragment length polymorphism
(RFLP) analysis [12]. RFLP is still most widely used in clinical microbiology laboratories due
to its simplicity and lower costs than PCR Sequencing [12]. Multiplex PCR has been used to
detect M. tuberculosis complex bacteria and other mycobacterium. This technique is based on
the amplification of the most widely used specific insertion sequences IS6110 and 16S [7-9].
Based on our experience, multiplex PCR has sensitivity up to 81.62% with negative predictive
value up to 79.51% [7]. Nevertheless, taking into account the “simple and economical” issue
this technique is probably not suited for most of the countries with a high tuberculosis burden
[11]. Other rapid molecular amplification detection method which is being used in our
laboratory is multiplex PCR-reverse cross blot hybridization, which can be modified to identify
multiple species of mycobacteria at one time by using a specific probe for each species.
Compared to the culture and microscopic method, this technique had a sensitivity of 86.03%,
negative predictive value of 82.41% and it can be applied to detect NTM [7]. The multiplex
PCR reverse cross blot hybridization technique is more complicated than conventional
multiplex PCR; but it can detect considerably more NTM species such as M. avium, M.
intracellulare, M. kansasii, M. fortuitum, M. chelonae, M. genavense and M. smegmatis (Fig. 1) [7].
In term of accuracy and duration time that it  needs to get a result,  Raman spectroscopy
is  one  of  the  most  promising  techniques.  This  vibrational  spectroscopy-based  detection
method  can  detect  and  differentiate  various  molecular  compositions  of  microorganism
[15-18]  and  therefore  is  suitable  to  identify  the  species  and  strains  of  microorganism.
Buijtels et al., demonstrated that Raman spectroscopy differentiated between M. tuberculo‐
sis with NTM with accuracy up to 100% and with 92.5% correct species identification. This
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technique is  also are  much faster;  results  can be obtained within 3  hours  since positive
automated cultured system is  obtained [18].  In view of  the importance of  early diagno‐
sis to prevent further spread of tuberculosis in the community, this time efficiency is the
most significant contribution of Raman spectroscopy.
Figure 1. Multiplex PCR reverse cross blot hybridization assay is able to detect various species of mycobacteria simulta‐
neously. Each column (Col) represents certain species of mycobacteria; Col 1, M. intracellulare; Col 2, M. kansasii ; Col
3-8, 11, 14, 20, 22, 24, 26, 28, 30-33, M. tuberculosis; Col 9, M. fortuitum; Col 10, 12, 13, M. chelonae; Col 15, 16, 18, 19,
23, 25, 27, 29, M. avium; Col 17, M. genavense; Col 21, M. smegmatis ; 34, pool PCR product of mycobacteria. [7]
3. Indirect detection methods
Even those remarkable molecular detection methods are not yet up to the mark when it comes
to in the identification of tuberculosis, particularly latent tuberculosis infection (LTBI). Approx‐
imately 2 milliard people are silent tuberculosis patients, i.e. they have been infected by M.
tuberculosis but show no tuberculosis symptoms [1, 2]. LTBI has been defined by evidence of a
cellular immune response to M. tuberculosis derived antigens. It may be the result of incom‐
plete elimination of M. tuberculosis by the host’s adaptive immune system, resulting in asympto‐
matic infection with almost undetectable bacilli [2]. Thus, the diagnosis of LTBI currently depends
on detecting the host’s immune response to the infection [2]. Affected individuals have little risk
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of progression from LTBI to active tuberculosis, but any disruption of their cellular immunity –
such as in HIV co-infection cases – can considerably increase this risk [2]. Currently, the diagnosis
of LTBI is commonly made with the tuberculosis skin test (TST), which is based on the delayed
hypersensitivity to purified protein derivative (PPD). Unfortunately, patients sensitized to
environmental nontuberculous mycobacteria or patients vaccinated with the bacillus Calmette–
Guérin (BCG) vaccine may have a false positive result. On the other hand, a false negative result
may occur in immunosuppressed patients and also in children [2]. This immunologic re‐
sponse is often not conclusive as antibodies and delayed type hypersensitivity response persist
long after infection or after the diseases has disappeared [12]
Interferon Gamma Release Assays (IGRAs) have been introduced in the clinical setting for the
diagnosis of LTBI [19-21]. These more specific whole-blood tests are based on the principle of
measuring host interferon-y (IFN-y) released by T-cells specific to M. tuberculosis as a marker.
IFN-y is stimulated by early secretory antigen target 6 (ESAT-6) and culture filtrate protein 10
(CFP-10). These are not present in the BCG or in the most of the NTM [2]. There are two types
of IGRAs: The enzyme-linked immunospot assay (ELISpot)-based IGRA, where individual
IFN-y producing T-cells responding to M. tuberculosis antigens stimulation are counted [22],
and the QuantiFERON-TB Gold In-Tube test, an ELISA-based IGRA where the IFN-y produced
by those T-cells is measured after stimulation with M. tuberculosis antigens [2]. Pai et al. showed
that the sensitivity of the ELISpot and ELISA-based approach was around 90% and 70%,
respectively, and that the specificity of both was 93% [2, 20]. As there is still no gold standard
for the diagnosis of LTBI, these assays potentially may serve as routine diagnosis test other
than TST to identify people with LTBI [2].
Cytokine-based detection methods could be useful not only in the detection of LTBI cases but
also of active tuberculosis cases. However, considering the high number of LTBI in the
community, a single cytokine identification method such as IGRAs is not sufficient to detect
active tuberculosis. For this reason the identification of multiple tuberculosis biomarkers-
cytokines seems to be a promising strategy. Several studies have shown the potential useful‐
ness of TNA-a, IL-2, IP-10, MIG along with IF-g simultaneously [23-26]. Using a multiplex
microbead-based assay, Wang et al. showed significant differences in expression of these
cytokines/chemokines between active tuberculosis patients and healthy controls. Regarding
active pulmonary tuberculosis the sensitivity of IFN-y, IP-10 and MIG was 75.3% and the
specificity was 89.7%. They also demonstrated the potential usefulness of this multiplex
microbead-based assay for the detection of new tuberculosis cases by documenting a sensi‐
tivity of 96.3% [23].
Untill now, smear and culture methods are still the gold standard to detect mycobacteria. Based
on our experience, combination of conventional and advanced detection methods would
greatly improve the sensitivity and specificity of the assays. Detection of the mycobacteria
species are quite difficult with culture, therefore we using multiplex PCR as the first confir‐
mation assay to detect the species while it also as confirmation test for negative results from
either smear or culture assay. Hence, to overcome the limitation of multiplex PCR in species
detection, multiplex PCR- reverse cross blot hybridization assay would further expand the
range of mycobacteria species detection (Fig. 2).
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Figure 2. Microbiologic diagnosis of tuberculosis. Multiplex PCR are used to confirm smears results and negative result
of culture assay. Patients with negative multiplex PCR result would be proceed for ELISpot or Tuberculin skin test (TST)
to detect latent tuberculosis (LTBI), while specimen from patient with positive culture result would get final confirma‐
tion by Multiplex PCR reverse cross blot hybridization assay to further detect the mycobacterium species
4. Conclusion
Conventional methods for the diagnosis of tuberculosis, such as the smear and culture methods
have some limitations, particularly the low specificity and sensitivity as well as the time-
consuming nature. Now these limitations have been overcome in some novel and rapid
detection methods. Various gene amplification techniques have demonstrated their usefulness
in the identification of mycobacteria and its various species. The rapid detection of M.
tuberculosis by probes, PCR or other molecular techniques and some newest serologic assays
offer good opportunities to improve the diagnosis and therapy of tuberculosis [2, 7-9, 12, 13].
However despite the availability of diagnostic tools for laboratory identification of tubercu‐
losis at high sensitivity and specificity, the “simple and economically” aspect of those new
methods is still a matter of consideration. The question is whether they can be used in simple
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clinical settings and whether they are economically affordable for developing countries, in
most of which tuberculosis is still rampant [11].
Summary
Tuberculosis still remains a major health problem in many developing countries, despite
continuous long-standing vaccination and surveillance programs, and worldwide availability
of effective anti-tuberculosis drugs. Early detection is of major importance in the control of
tuberculosis. The emergence of multidrug resistant Mycobacterium tuberculosis and the
association of HIV with tuberculosis outbreaks in community both illustrate that rapid
diagnosis is essential. Therefore, a fast and reliable diagnosis of tuberculosis would greatly
improve the control of the tuberculosis. Regrettably, current conventional laboratory diag‐
nostic methods of tuberculosis are still time-consuming. The rapid development of novel
diagnostic methods for the identification of mycobacteria and its species bring new hope,
however, for the diagnosis and management this infectious disease. Meanwhile those techni‐
ques still seem to clash with simplicity and economically affordable issues.
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